ARTICLE | Finance
Mersana's clinical cash
Mersana looks to bring ADCs to clinic with $35M, new CEO
March 9, 2015 7:00 AM UTC
A fresh infusion of cash and a new CEO should facilitate Mersana Therapeutics Inc.'s transition from an ADC platform company into a clinical-stage drug development company.
In 2012, Mersana raised $27 million in a series A-1 round to reposition the company's Fleximer technology for the development of ADCs. Over the past three years Mersana has been optimizing the technology and added ADC partnerships with Adimab LLC, Endo International plc (NASDAQ:ENDP; TSX:ENL), the Merck Serono unit of Merck KGaA (Xetra:MRK) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)...